Werkgroep Cardiologische centra Nederland

EMPA-RESPONSE (Follow-up)

Randomized, double blind, placebo controlled, multicenter pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure
Medicine
empagliflozin
Population
Heart failure
Phase
II
Starting year
2017